Gene23 Limited 15777549 false 2024-06-13 2025-06-30 2025-06-30 The principal activity of the company is Other human health activities Digita Accounts Production Advanced 6.30.9574.0 true true 15777549 2024-06-13 2025-06-30 15777549 2025-06-30 15777549 bus:OrdinaryShareClass1 bus:OtherShareType 2025-06-30 15777549 core:CurrentFinancialInstruments core:WithinOneYear 2025-06-30 15777549 bus:SmallEntities 2024-06-13 2025-06-30 15777549 bus:AuditExemptWithAccountantsReport 2024-06-13 2025-06-30 15777549 bus:FilletedAccounts 2024-06-13 2025-06-30 15777549 bus:SmallCompaniesRegimeForAccounts 2024-06-13 2025-06-30 15777549 bus:RegisteredOffice 2024-06-13 2025-06-30 15777549 bus:Director1 2024-06-13 2025-06-30 15777549 bus:OrdinaryShareClass1 bus:OtherShareType 2024-06-13 2025-06-30 15777549 bus:PrivateLimitedCompanyLtd 2024-06-13 2025-06-30 15777549 core:FurnitureFittingsToolsEquipment 2024-06-13 2025-06-30 15777549 core:OfficeEquipment 2024-06-13 2025-06-30 15777549 countries:AllCountries 2024-06-13 2025-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 15777549

Gene23 Limited
Unaudited Filleted Abridged Financial Statements
for the Period from 13 June 2024 to 30 June 2025

Gene23 Limited

Contents

Company Information | 1
Abridged Balance Sheet | 2
Notes to the Unaudited Abridged Financial Statements | 3 to 5

Gene23 Limited

Company Information

Director | Ms Ahmirin Shah

Registered office | 138 Bury Old Road Whitefield Manchester Greater Manchester M45 6AT

Gene23 Limited

(Registration number: 15777549)
Abridged Balance Sheet as at 30 June 2025

| Note | 2025 £
Fixed assets |  |
Tangible assets |  | 9,153
Current assets |  |
Cash at bank and in hand |  | 789
Creditors: Amounts falling due within one year |  | (5,912)
Net current liabilities |  | (5,123)
Total assets less current liabilities |  | 4,030
Accruals and deferred income |  | (750)
Net assets |  | 3,280
Capital and reserves |  |
Called up share capital | 4 | 300
Retained earnings |  | 2,980
Shareholders' funds |  | 3,280

For the financial period ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and
• | The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 30 September 2025

......................................... Ms Ahmirin Shah Director

Gene23 Limited

Notes to the Unaudited Abridged Financial Statements for the Period from 13 June 2024 to 30 June 2025

1 | General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
138 Bury Old Road
Whitefield
Manchester
Greater Manchester
M45 6AT
England

These financial statements were authorised for issue by the director on 30 September 2025.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Gene23 Limited

Notes to the Unaudited Abridged Financial Statements for the Period from 13 June 2024 to 30 June 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Office Equipment | 20% Per Annum Reducing Balance Basis
Fixtures & Fittings | 20% Per Annum Reducing Balance Basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3 | Staff numbers

The average number of persons employed by the company (including the director) during the period, was 1.

4 | Share capital

Allotted, called up and fully paid shares

Gene23 Limited

Notes to the Unaudited Abridged Financial Statements for the Period from 13 June 2024 to 30 June 2025

| 2025
| No. | £
Ordinary Share Capital of £1 each | 300 | 300